VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo
VIS832是一种新型的靶向CD138的单克隆抗体，能够有效杀伤人多发性骨髓瘤细胞，并且在体外和体内均能与免疫调节剂（IMiDs）或硼替佐米产生协同作用。
期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-020-00378-z
Yu, Tengteng; Chaganty, Bharat; Lin, Liang; Xing, Lijie; Ramakrishnan, Boopathy; Wen, Kenneth; Hsieh, Phillip A; Wollacott, Andrew; Viswanathan, Karthik; Adari, Hedy; Cho, Shih-Feng; Li, Yuyin; Chen, Hailin; Yang, Wenjuan; Xu, Yan; An, Gang; Qiu, Lugui; Munshi, Nikhil; Babcock, Gregory; Shriver, Zachary; Myette, James R; Anderson, Kenneth C; Tai, Yu-Tzu
单克隆抗体
多发性骨髓瘤
骨髓瘤
细胞生物学
CD13
CD138
免疫/内分泌
